Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
The Evolution of Liver Care: From NASH to MASH and Beyond For years, the medical community focused on Non-Alcoholic Steatohepatitis (NASH). However, a pivotal shift in terminology to Metabolic-dysfunction Associated Steatohepatitis (MASH) isn’t just a semantic change—it reflects a deeper understanding of how metabolic health drives liver disease. MASH is a silent progression, often leading … Read more